Antibodies to IL-17A
View Patent ↗Engineered antibodies to human IL-17A are provided, as well as uses thereof.
1. An isolated binding compound that binds to human IL-17A, comprising:
at least one antibody light chain variable region and
at least one antibody heavy chain variable region,
wherein the light chain variable region comprises the CDR sequences of SEQ ID NOs: 11, 12 and 13; and
wherein the heavy chain variable region comprises the CDR sequences of SEQ ID NOs: 14, 17 and 20.
2. The binding compound of claim 1 , wherein the heavy chain variable region comprises the CDR sequences of SEQ ID NOs: 14, 16 and 19.
3. The binding compound of claim 2 , wherein the light chain variable region comprises the sequence of SEQ ID NO:5 having the CDR sequences of SEQ ID NOs: 11, 12 and 13 and up to ten conservative amino acid substitutions in the framework residues and wherein the heavy chain variable region comprises the sequence of SEQ ID NO:6 having the CDR sequences of SEQ ID NOs: 14, 16 and 19 and up to ten conservative amino acid substitutions in the framework residues.
4. The binding compound of claim 1 , wherein the binding compound is an antibody comprising:
a light chain variable region that comprises SEQ ID NO: 5; and
a heavy chain variable region that comprises SEQ ID NO: 6.
5. The binding compound of claim 1 , wherein the light chain consists essentially of amino acids 1-220 of SEQ ID NO:2 having the CDR sequences of SEQ ID NOs: 11, 12 and 13 and up to ten conservative amino acid substitutions in the constant region.
6. The binding compound of claim 4 , wherein the light chain consists essentially of amino acids 1-220 of SEQ ID NO: 2 and the heavy chain consists essentially of amino acids 1-454 of SEQ ID NO: 4.
7. The binding compound of claim 6 , wherein the light chain consists of amino acids 1-220 of SEQ ID NO: 2 and the heavy chain consists of amino acids 1-454 of SEQ ID NO: 4.
8. An isolated binding compound that binds to human IL-17A, wherein the binding compound comprises:
an antibody light chain having the CDR sequences of SEQ ID NOs: 11, 12 and 13and at least 95% sequence identity with amino acids 1-220 of SEQ ID NO: 2; and
an antibody heavy chain having the CDR sequences of SEQ ID NOs: 14, 16 and 19 and at least 95% sequence identity with amino acids 1-454 of SEQ ID NO: 4.
9. An isolated anti-human IL-17A antibody hu16C10, wherein the amino acid sequence of the antibody is encoded by the expression vector having ATCC Accession No. PTA-7675.
10. The binding compound of claim 1 , wherein the binding compound is a humanized or fully-human monoclonal antibody.
11. A composition comprising:
a binding compound that binds to human IL-17A and neutralizes human IL-17A activity, wherein the binding compound comprises an antibody light chain variable region and an antibody heavy chain variable region, wherein the light chain variable region comprises SEQ ID NO: 5 and the heavy chain variable region comprises SEQ ID NO: 6; and
a pharmaceutically acceptable carrier or diluent.
12. The composition of claim 11 , further comprising another immunosuppressive or anti-inflammatory agent.
13. The binding compound of claim 2 , further comprising a heavy chain constant region, wherein the heavy chain constant region comprises a γ1, γ2, γ3, or γ4 human heavy chain constant region.
14. The binding compound of claim 13 , wherein the heavy chain constant region comprises a γ1 human heavy chain constant region.
15. The binding compound of claim 13 , wherein the heavy chain constant region comprises a γ4 human heavy chain constant region.
16. The binding compound of claim 2 , further comprising a light chain constant region, wherein the light chain constant region comprises a kappa human light chain constant region.
17. The binding compound of claim 2 , wherein the binding compound is an antibody fragment selected from the group consisting of Fab, Fab′, Fab′-SH, Fv, scFv, F(ab′) 2 , and a diabody.
18. The binding compound of claim 3 , wherein the binding compound is an antibody fragment selected from the group consisting of Fab, Fab′, Fab′-SH, Fv, scFv, F(ab′) 2 , and a diabody.
19. The binding compound of any of claim 1 or 8 , wherein the binding compound inhibits human IL-17A activity.